Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

@article{Izquierdo2008PhaseIC,
  title={Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.},
  author={Miguel Angel Izquierdo and Angela Bowman and Margarita Garc{\'i}a and Duncan I. Jodrell and Marisa Mart{\'i}nez and Beatriz Pardo and Javier Mauricio Mart{\'i}nez G{\'o}mez and Jose Antonio L{\'o}pez-Mart{\'i}n and Jos{\'e} Carlos Pastor Jimeno and Josep Ram{\'o}n Germ{\`a} and John F. Smyth},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 10},
  pages={3105-12}
}
PURPOSE Plitidepsin, given as a 1-hour weekly i.v. infusion for 3 consecutive weeks during a 4-week treatment cycle, was investigated in patients with solid tumors to determine the maximum tolerated dose and the recommended dose (RD) using this administration schedule. EXPERIMENTAL DESIGN Consecutive cohorts of patients with metastatic solid tumors or non-Hodgkin's lymphomas were to be treated at escalating doses of plitidepsin in a conventional phase I study including pharmacokinetic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…